JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M106425200 on August 24, 2001

J. Biol. Chem., Vol. 276, Issue 43, 39618-39628, October 26, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/43/39618    most recent
M106425200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Filipe, S. R.
Right arrow Articles by Tomasz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Filipe, S. R.
Right arrow Articles by Tomasz, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Functional Analysis of Streptococcus pneumoniae MurM Reveals the Region Responsible for Its Specificity in the Synthesis of Branched Cell Wall Peptides*

Sergio R. FilipeDagger §, Elena SeverinaDagger ||, and Alexander TomaszDagger **

From the Dagger  Laboratory of Microbiology, The Rockefeller University, New York, New York 10021 and the § Molecular Genetics Unit, Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, 2780 Oeiras, Portugal

Received for publication, July 9, 2001, and in revised form, August 22, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The recently identified murMN operon of Streptococcus pneumoniae encodes enzymes involved in the synthesis of branched structured muropeptides of the pneumococcal cell wall peptidoglycan. Its inactivation was shown to cause production of a peptidoglycan composed exclusively of linear muropeptides and a virtually complete loss of resistance in penicillin-resistant strains. The studies described in this communication follow up these observations in several directions. The substrate of the MurM-catalyzed reaction (addition of alanine or serine) was identified as the lipid-linked N-acetylglucosamine-muramyl pentapeptide. Different murM alleles from several penicillin-resistant S. pneumoniae strains, each with a characteristic branched peptide pattern, were cloned into pLS578, a pneumococcal plasmid capable of replicating in S. pneumoniae, and transformed into the penicillin-susceptible laboratory strain R36A. All transformants remained penicillin-susceptible; however, their cell wall composition changed in directions corresponding to the muropeptide pattern of the strain from which the murM allele was derived. This suggests that the muropeptide composition of the pneumococcal cell walls is determined by the particular murM allele carried by the cells. A 30-amino acid long sequence within the MurM protein was shown to be the main determinant of the specificity of the reaction (addition of alanine versus serine).


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The synthesis of the peptidoglycan in bacteria may be divided into three stages: in the first, cytoplasmic, stage several consecutive enzymatic reactions synthesize the peptidoglycan building block, the UDP-MurNAc-pentapeptide. In the case of Streptococcus pneumoniae and several other bacteria, the pentapeptide chain is composed of L-alanine, D-isoglutamine, L-lysine, D-alanine, D-alanine, with the latter representing the C-terminal residue. The second stage of synthesis occurs in the plasma membrane where the peptidoglycan building block is linked to a bactoprenol residue and may undergo a "maturation process" by several as yet not well understood enzymatic reactions. These may include addition of short peptides to the lysine epsilon amino group in some or all of the stem peptides; and amidation of the second stem peptide residue, usually a glutamate, to glutamine. After addition of an N-acetyl glucosamine residue, the bactoprenol-linked and structurally completed disaccharide pentapeptide peptidoglycan precursor is transferred to the outer side of the plasma membrane for presentation to proteins (monofunctional transglycosylases, penicillin binding proteins) that take part in the assembly of the macromolecular peptidoglycan.

The pneumococcal peptidoglycan is composed of both linear and branched muropeptides, the latter of which carry short dipeptide branches. The chemical nature of the branched peptides, seryl "alanine or alanyl" alanine, i.e. the type of muropeptide they are attached to and the proportion of muropeptides carrying branches vary from strain to strain (1-3). The identification of the murMN operon opened up new experimental approaches for the study of the mechanism of synthesis and physiological role of branched peptides. Most interestingly, inactivation of the murMN was shown to cause not only the production of cell wall peptidoglycan composed exclusively of linear muropeptides but also a complete loss of the resistant phenotype in penicillin-resistant strains (4). Several penicillin-resistant isolates were shown to carry murM genes with unique polymorphic regions, which seem to correlate with the preponderance of seryl-alanine or alanyl-alanine branches in the peptidoglycan (5). Selective inactivation of murM and murN showed that the protein products of these genes act in sequence: murM being involved with the addition of the first amino acid (serine or alanine) and murN involved with the addition of second amino acid of the bridge (alanine) (6).

The main purpose of the studies described here was to identify the substrate of the MurM-catalyzed reaction and to better define the roles of various murM alleles in defining cell wall composition and penicillin resistance.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Strains, Growth Conditions, and Antibiotic Susceptibility Tests-- All strains and plasmids used in this study are listed below in Table I. S. pneumoniae strains were grown in a casein-based semisynthetic medium at 37 °C without aeration, as previously described (1). S. pneumoniae strains containing pLS578 or its derivatives were grown in the presence of 1 µg/ml tetracycline, and Escherichia coli strains containing pGEM-3Z plasmid or its derivatives were grown in the presence of 100 µg/ml ampicillin (Sigma Chemical Co.).

Penicillin-resistance levels (minimal inhibitory concentration, MIC1) were determined by the E test following manufacturer's guidelines (AB Bidosk, Solna, Sweden).

DNA Techniques-- All routine DNA manipulations were performed using standard methods (11, 12). Chromosomal DNA from S. pneumoniae was isolated as described previously (13). Plasmids were isolated using the Wizard Plus Minipreps or Midipreps DNA purification system (Promega), and PCR products were purified using the Wizard PCR Preps DNA purification system (Promega). Oligonucleotides were purchased from Life Technologies, Inc. DNA sequencing was done at the Rockefeller University Protein/DNA Technology Center with the BigDye terminator cycle sequencing method and either the 3700 DNA analyzer for capillary electrophoresis or the ABI Prism 377 DNA sequencer for slab-gel electrophoresis. Nucleotide and derived amino acid sequences were analyzed using DNASTAR software.

Construction of S. pneumoniae Lacking murM-- To isolate a mutant of the penicillin-resistant strain Pen6 lacking murM gene, we transformed Pen6 with a PCR fragment that included the 2-kb fragment from pJDC9, containing the erm marker, flanked by the regions upstream and downstream of murM.

To obtain this PCR fragment the upstream and downstream segments of murM were amplified from chromosomal DNA of strain Pen6 by PCR with PfuTurbo DNA polymerase (Stratagene). First, the 0.46-kb PCR fragment containing the upstream region of murM was amplified with primers ZOO45EC (5'-AGCGAATTCGGTTTTGACTACTACACGGC-3') and ZOO46BM (5'-ATAGGATCCTTTCCCAGTAGTACCACTCG-3'), digested with EcoRI and BamHI and cloned into plasmid pGEM-3Z generating plasmid pZ009. The EcoRI and BamHI restriction sites are underlined in the primers. Next the HindIII/PstI-digested 0.54-kb PCR fragment containing the downstream region of murM was amplified with primers ZOO47PS (5'-GCGCTGCAGAGTCGGCAGCGACTCATAGAAT-3') and ZOO2BM (5'-TATGGATCCAGTCTCGCGCTTCTGCTTTTC-3'), and was cloned into pZ009 yielding pZ0010. The underlined sequence indicates the PstI restriction site. Finally the 2-kb BamHI/ClaI fragment from pJDC9 containing the erm marker was cloned into the BamHI/AccI-digested plasmid pZOO10 generating pZ0011. Plasmid pZ0011 contains the erm marker flanked by the upstream and downstream regions of murM. The transforming DNA used to prepare the murM null mutant of strain Pen6 was a PCR fragment of plasmid pZOO11 amplified with primers ZOO30 (5'-ATATTCTCTACGTTCAGAGG-3') and ZOO45EC (5'-AGCGAATTCGGTTTTGACTACTACACGGC-3'). The conditions used for the PCR reactions were: 94 °C for 5 min; 30 cycles of 94 °C for 30 s, 53 °C for 30 s, and 72 °C for 2 min; and one final extension step of 72 °C for 5 min. This PCR program was used for all amplifications except the extension time at 72 °C, which was different depending on the size of the PCR fragment to be amplified. The deletion of murM in the erythromycin-resistant Pen6Delta murM mutant was confirmed by PCR amplification and subsequent sequencing.

Transformation of S. pneumoniae-- Transformation of S. pneumoniae R36A strain was carried out similarly to the already described procedure (14) except that the concentration of peptide pheromone was 500 ng/ml and the transforming reaction was held at 37 °C for 4 h before plating in selective plates of TSA+3% (v/v) sheep blood and 1 µg/ml tetracycline. The different murM alleles cloned in pLS578 and transformed into R36A strain were specifically amplified with primers that hybridize in the plasmid: TETDPLS (5'-CCTATGGAAGTTGATCAGTC-3') and CATR (5'-CATGRTAACCATCACAWACAG-3').

Construction and Cloning of the Different murM Alleles into S. pneumoniae-- Several murM constructs were prepared, each in the S. pneumoniae plasmid pLS578, a plasmid with a strong promoter that can replicate in S. pneumoniae (10). Three S. pneumoniae strains were used as sources of murM alleles: the penicillin-susceptible laboratory strain R36A, the penicillin-resistant strain DE1 producing alanine-rich branches in the cell wall, and the penicillin-resistant strain KY17 producing serine-rich branches.

The first one of such plasmid constructs carried the murM allele from strain R36A. The murM gene was amplified as a PCR fragment from the chromosomal DNA using primers ZOO48HI (5'-CCCAAGCTTAAAATACTGGAGGAAAGAGAG-3') and ZOO49NC (5'-CATGCCATGGGCCATATAC<UNL>TTA</UNL>CTTTCTATG-3') with PfuTurbo DNA polymerase (Stratagene) (the HindIII and NcoI restriction sites are underlined and the stop codon is double-underlined) and was cloned into the 4.5-kb HindIII/NcoI-digested fragment of pLS578, yielding plasmid pM1.

The second and third plasmids were constructed by the same procedure using chromosomal DNA either from penicillin-resistant strain DE1 (plasmid pM2) or from the penicillin-resistant strain of KY17 (plasmid pM3).

MurM Chimera Mutants-- Another set of plasmids was constructed in such a way that segments of the 406-amino acid long MurM would be derived from various murM alleles carried by the penicillin-susceptible strain R36A or the penicillin-resistant strains DE1 or KY17.

The first one of these plasmids, pM9, contained a cloned chimeric MurM that was composed of residues 1-240 with equal sequence to the MurM of the penicillin-susceptible strain R36A fused the remaining 166 amino acids residues of the penicillin-resistant strain DE1.

Plasmid pM9 was constructed in several steps. A PCR fragment encoding for the C terminus 166 amino acid residues (from 241 to 406) of strain DE1 was amplified with the primers MMUT4 (5'-CCCAAGCTTGCTCTAGATGTTTCTAAGCGTTTAAG-5', where the HindIII and XbaI restriction sites are underlined) and ZOO49NC (see above) from chromosomal DNA and cloned into the HindIII/NcoI-digested E. coli plasmid pSF22 (pGEM-3Z carrying a promoterless murN and an NcoI restriction site (see Table I below), yielding plasmid pSF24. Next, the full murM gene was reconstructed by cloning in this plasmid (digested with HindIII and XbaI) the PCR product obtained from the chromosomal DNA of strain R36A with the primers ZOO48HI (see above) and MMUT3 (5'-GCATCTAGAGTTGCCAAGGTGATGTAG-3', where the XbaI restriction site is underlined), generating a plasmid named pSF25. Finally, the chimeric murM gene was transferred from pSF25 to the pneumococcal plasmid pLS578 by the following operations. The chimeric mutant murM was amplified from plasmid pSF25 using primers ZOO48HI and ZOO49NC (see above) and cloned into the HindIII/NcoI-digested pLS578 plasmid. This pneumococcal plasmid, carrying the murM chimera mutant gene from the penicillin-resistant strain R36A and DE1 was named pM9.

The second chimeric plasmid pM10 included a PCR fragment that encoded for the 240 amino acid residues from the N terminus of the penicillin-resistant strain KY17 (from 1 to 240) fused with the remaining 166 amino acid residues from another penicillin-resistant strain DE1 (from 241 to 406).

Plasmid pM10 was constructed in a way similar to that used in the construction of pM9. A PCR fragment encoding for the 240 amino acid residues from the position 1-240 was amplified with the primers ZOO48HI and MMUT3 (see above) from the KY17 chromosomal DNA and cloned into the HindIII/XbaI-digested pSF24 plasmid, generating the plasmid pSF26. Procedures similar to the ones used in the construction of pM9 were employed for the transfer of the murM chimera from the E. coli plasmid pSF26 to the pneumococcal plasmid pLS578 generating the plasmid pM10.

An additional set of plasmids carrying chimeric murM mutants were constructed to more precisely define the region controlling the specificity of the reaction catalyzed by the MurM protein.

Plasmid pM11 carried a murM allele that was identical to that from strain KY17 (the MurM of which mainly adds serine residues to the muropeptide cross-bridges) except for the position between residues 244 and 298, which was replaced by the corresponding sequence from the murM of strain DE1 (the MurM of which mainly adds alanine residues to the muropeptide cross-bridges).

Plasmid pM11 was constructed in several steps. A PCR fragment comprising the sequence that encodes for the residues from position 300 to the end of the MurM protein (the 106 amino acid residues from the C terminus) of strain KY17 was amplified with primers ZOO49NC (see above) and MMUT18 (5'-CGCAAGCTTCTCGAGTTTGGTACTACCTCTGTCAATC-3' from plasmid pSF27, where the HindIII and XhoI restriction sites are underlined). This PCR fragment was cloned into the HindIII/NcoI-digested plasmid pSF22, yielding plasmid pSF28. Next, the full gene was reconstructed by cloning in pSF28 (digested with HindIII and XhoI) the PCR product that encoded the amino acid residues from position 1 to 300, obtained with the primers ZOO48HI (see above) and MMUT19 (5'-TTCCTCGAGACTCAAAGTAGCCGCTAAG-3') from pSF26 (the XhoI restriction site is underlined). The resulting plasmid, pSF29, carried a chimeric MurM protein that was equal to the KY17 MurM except between residues 244 and 298, which were the same as those found in the DE1 MurM. Finally, the chimeric murM gene was amplified from plasmid pSF29 using primers ZOO48HI and ZOO49NC (see above) and cloned into the HindIII/NcoI-digested pLS578 plasmid, yielding the plasmid pM11.

An additional murM chimera mutant, pM12, was constructed in a similar way as described for pM11, but this time only the segment between residues 244 and 274 was derived from the MurM of strain DE1.

As in the case of pM11, here too, the chimera mutant was initially constructed in an E. coli plasmid. The PCR product obtained from plasmid pSF27 with primers ZOO49NC and MMUT16 (5'-CGCAAGCTTCTCGAGGAATTGACTTTCCTGCAGG-3', where the HindIII and XhoI restriction sites are underlined), was first cloned into the HindIII/NcoI-digested pSF22 plasmid. The resulting plasmid, pSF30, carried a DNA fragment that encoded the residues from 276 to the end of the protein (the last 131 residues from the C terminus) of the murM of strain KY17. The DNA fragment coding for the remaining 275 amino acids was amplified with primers ZOO48HI (see above) and MMUT17 (5'-TTCCTCGAGTAAACGTTCTTTTTCTTTTATATTTTCCTG-3') from pSF26 and cloned to the HindIII/XhoI-digested pSF30 plasmid, yielding the plasmid pSF31. This plasmid carried a chimeric MurM protein that was equal to the KY17 MurM except for the position between residues 244 and 274, which came from the murM of strain DE1. After amplification from plasmid pSF31 with primers ZOO48HI and ZOO49NC (see above), the murM chimera was cloned into the HindIII/NcoI-digested pLS578 plasmid, yielding the plasmid pM12.

MurM deletion Mutants-- Several simple variants of plasmid pM3, each carrying incomplete murM genes from strain KY17, were also constructed.

In plasmid pM13, 50 residues of the C terminus of MurM were deleted by cloning into the pLS578 plasmid a PCR fragment amplified by the following pair of primers: ZOO48HI (see above) and MDC355N (5'-AATGCCATGGTTA<UNL>TTA</UNL>GTTTTCAACACCACC-3') that includes a NcoI restriction site (underlined) and a premature stop codon (double-underlined).

In plasmid pM14, 50 residues of the N-terminal of MurM were deleted by cloning into the pLS578 plasmid a PCR fragment amplified by the following pair of primers, ZOO49NC (see above) and MDNM68 (5'-ATCAAGCTTAAGGAGGCTATAAA<UNL>ATG</UNL>TTTTACATCCCA-3'), which includes an HindIII restriction site (underlined) and an initiation codon (double-underlined).

In plasmid pM15, 10 residues were deleted from the C terminus by cloning into the pLS578 plasmid the PCR product from the KY17 chromosomal DNA using primers ZOO48HI AND MDC396F (5'-CATGCCATGGTTAGAAATCAAGAGCAAGTCTTAACAG-3'), which includes an NcoI restriction site (underlined) and a premature stop codon (double-underlined).

In plasmid pM16, the segment between residues 240 and 275 was deleted. To construct this murM deletion mutant we cloned into the E. coli HindIII/XhoI-digested plasmid pSF30 (that carries a DNA fragment encoding the last 131 residues of the C-terminal from KY17 MurM) the PCR product obtained with primers ZOO48HI and MMUT3 from the KY17 chromosomal DNA. This PCR product encodes the first 240 amino acid residues from the N terminus. The resulting plasmid, pSF32, carried a murM gene that coded for a protein equal to KY17 except for the deletion between residues 240 and 275. The murM with the deletion was then amplified with primers ZOO48HI and ZOO49NC (see above) and cloned into the pneumococcal plasmid pLS578, yielding the plasmid pM16.

Single Residue MurM Mutants-- The murM allele from KY17 was also mutated to test the possible importance of some amino acid residues for the specificity of the MurM-catalyzed reaction. The particular residues tested were threonine in position 260 and glutamine in position 27 of the MurM protein. In plasmid pM17 the threonine residue at position 260 of the KY17 murM was mutated to lysine, whereas in plasmids pM18 and pM19 the glutamine residues at position 27 were mutated to either glutamate (pM18) or to threonine (pM19).

The following procedures were used. First, the murM gene was amplified from chromosomal DNA of strain KY17 using primers ZOO48HI and ZOO49NC (see above) and cloned into the HindIII/NcoI site of pSF22, yielding the plasmid pSF23. Then the threonine in the position 260 of the cloned murM was mutated to a lysine using the QuikChange site-directed mutagenesis kit (Stratagene) and the primer PDT260K (5'-GAGCCTTGGAAGAGAAGTTTACTGAGTCGACTCGC-3') and its reverse PRT260K, yielding the plasmid pSF33 (the mutated codon is in boldface). The glutamine residue in position 27 was also mutated by the same procedure to a glutamate with the primer PDQ27E (5'-GAATTAGCCAATGTATTAGAAAGTAGTGCTTGGGAAG-3') and its reverse PRQ27E, and to a threonine with the primer PDQ27T (5'-GAATTAGCCAATGTATTAACCAGTAGTGCTTGGGAAG-3') and its reverse, yielding the plasmids pSF34 and pSF35, respectively (the mutated codons are in boldface). Both mutations were confirmed by sequencing. Eventually the mutant murM genes were then transferred to the pneumococcal plasmid pLS578.

Cell Wall Preparation and Enzymatic Digestion-- Pneumococcal cell walls were prepared by a previously published method (2, 15) except for the process of breaking the cells that was done by shaking with acid-washed glass beads with the help of FastPrep FP120 (BIO 101 Inc.). Cell wall material (2 mg) was suspended in 25 mM sodium phosphate buffer, pH 7.4, and treated with affinity-purified pneumococcal amidase (5-10 µg) at 37 °C for 12-18 h with constant stirring. The products were dried, the precipitate was washed with acetone, and the peptides were extracted with acetonitrile-isopropanol-water (25:25:50, v/v) containing 0.1% trifluoroacetic acid as already described (2, 15, 16). After removal of the solvents by evaporation in a SpeedVac, the peptides were dissolved in 0.1% trifluoroacetic acid.

Separation and Analysis of the Cell Wall Stem Peptides-- Peptides were separated with a Shimadzu LC-10AVP HPLC system, as described previously (2). The column used was a Vydac model 218TP54 (The Separations Group). Peptides were eluted with an 80-min linear gradient from 0 to 15% acetonitrile (Fisher) in 0.1% trifluoroacetic acid (Pierce) pumped at a flow rate of 0.5 ml/min. The eluted fractions were detected and quantified by determination of their UV absorption at 210 nm (A210).

Isolation and Analysis of S. pneumoniae Peptidoglycan Precursors-- For analysis of cytoplasmic (UDP-linked) peptidoglycan precursors of S. pneumoniae cultures were grown in C+Y medium to an A590 nm of 0.3 at which time vancomycin was added at a final concentration of 5 µg/ml (10× MIC). The cultures were incubated for 60 min, harvested by centrifugation, and washed with 50 mM Tris-HCl, pH 8.0. The UDP-linked cell wall precursors were extracted by cold 5% trichloroacetic acid for 30 min. The extract containing the pool of precursors was separated by gel filtration on a Sephadex G-25 column (Amersham Pharmacia Biotech) and eluted with water. The precursor compounds were then applied to a 3.9- × 30-mm reversed-phase column (µBondapack C18, Waters) as previously described (17) except that the UDP-linked precursors were eluted with an 80-min linear gradient from 0 to 15% of acetonitrile (Fisher) in 0.1% trifluoroacetic acid (Pierce) pumped at a flow rate of 0.5 ml/min. The eluted fractions were detected and quantified by determination of their UV absorption at 254 nm.

Lipid-linked cell wall precursors were prepared essentially as described by Kohlrausch and Holtje (18). Cultures were grown in C+Y medium to an A590 nm of 0.3 at which time vancomycin at a final concentration of 5 µg/ml (10× MIC) was added. The cultures were incubated for one additional generation period, harvested by centrifugation, and washed with 50 mM Tris-HCl buffer, pH 8.0. The lipid-linked precursors were extracted with ice-cold n-butanol/6 M pyridinium acetate (pH 4) (4:1) by shaking with glass beads with the help of FastPrep FP120 (BIO 101 Inc.). The organic phase was collected, washed twice with 1 volume of water, and dried in a SpeedVac. The lipid precursors in the organic extraction phase were hydrolyzed with 0.1 M HCl for 15 min in a boiling water bath to yield GlcNAcbeta -1,4-MurNAc peptide derivatives. Before HPLC separation, one volume of 0.5 M borate buffer, pH 9.0, was added to this muramyl residue-containing fraction. The muramyl residues were then reduced to muramitol derivatives with sodium borohydride and analyzed by reverse-phased HPLC, as previously described (19). The amino acid composition (20) of the eluted peaks was determined at the Rockefeller University Protein/DNA Technology Center.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Addition of Peptide Branches to the S. pneumoniae Muropeptides Occurs in the Plasma Membrane Fraction-- To identify the step of the cell wall biosynthetic pathway in which serine or alanine are added to the epsilon -amino group of the muropeptide lysine residues, we determined the composition of the cytoplasmic and lipid-linked precursors in the penicillin-resistant S. pneumoniae strain Pen6 and its murM deletion mutant (Table I). Both cultures were grown to early exponential phase, at which time vancomycin was added to cause accumulation of UDP-linked (cytoplasmic) or lipid-linked (plasma membrane) cell wall precursors. After removal of the lipid carrier by mild acid hydrolysis, followed by sodium borohydride reduction of the released muropeptide component(s), these were analyzed by RP-HPLC and their amino acid compositions were determined. In the lipid extract of the Pen6 murM null mutant, one major peak c was identified (Fig. 1A). Two small additional peaks were also consistently detected. The chemical nature of these is unknown. Amino acid analysis showed the presence of glutamic acid, lysine, and alanine in the molar ratio of 1.0, 0.8, and 2.75 suggesting an unsubstituted disaccharide pentapeptide (Glu 1.0, Lys 1.0, Ala 3.0). Peak c had a retention time on the RP-HPLC column identical to that of the unsubstituted disaccharide pentapeptide component of Staphylococcus aureus peptidoglycan (19).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Relevant properties of the strains and plasmids used in this study


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Analysis of the cell wall precursors by RP-HPLC of Pen6 and its murM deletion mutant. Lipid-linked precursors (A) and UDP-linked precursors (B) from Pen6 and its murM deletion mutant were prepared, and its composition was determined by HPLC as described under "Experimental Procedures."

The lipid extract of strain Pen6 showed accumulation of 2 major peaks (Fig. 1A). Several additional minor peaks were also present. The nature of these is not known at the present time. Amino acid analysis of peak a showed the presence of glutamic acid, lysine, alanine, and serine in the molar ratios of 1.0, 0.8, 3.8, and 1.1, which is consistent with the structure of a disaccharide pentapeptide carrying a seryl-alanine branch (Glu 1.0, Lys 1.0, Ala 4.0, Ser 1.0). Amino acid analysis of the second peak b showed the presence of glutamic acid (1.0), lysine (0.8), and alanine (4.4) with small amounts of contaminating serine consistent with the structure of peak b as the disaccharide pentapeptide containing an alanyl-alanine branch. The small deficit in alanine content (4.4 mol instead of the expected 5.0) together with the presence of small amounts of serine indicate peak b also contains small amounts of seryl-alanine-containing muropeptide. The relative amounts of peak a to peak b was 59 and 41%, respectively, similar to the ratio of seryl-alanine (55%)- and alanyl-alanine (45%)-containing muropeptides in the peptidoglycan of strain Pen6 (Table II) (4).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Cell wall peptide composition of several strains of S. pneumoniae

To rule out that the reaction catalyzed by MurM (addition of serine or alanine to the epsilon -amino group of the lysine residue) may also occur in the cytoplasmic fraction, we analyzed the composition of the UDP-linked precursors in the Pen6 and its murM null mutant. Extracts from both strains showed accumulation of a single major peak a and two smaller peaks (Fig. 1B). Peak a had the same retention time on the RP-HPLC column as the UDP-linked disaccharide pentapeptide identified in the cytoplasmic cell wall precursor fraction of several bacteria (17). The nature of the smaller peaks is not known.

Alterations in the Cell Wall Composition of S. pneumoniae Strain R36A Carrying Different murM Alleles on Plasmids-- Three murM alleles described previously (5) were cloned in the pLS578 plasmid and transformed into strain R36A (a penicillin-susceptible laboratory strain with a relatively low percentage of branched stem peptides). Two of the murM alleles cloned into pLS758 had mosaic structure and came from the penicillin-resistant clinical isolates DE1 and KY17 (5). The third murM came from strain R36A. The peptidoglycan of the two penicillin-resistant strains had a high proportion of branched muropeptides: 77% in strain DE1 and 84% in KY17, as compared with strain R36A in which only 41% of muropeptides had branched structure. The two penicillin-resistant strains also had distinct cell wall stem peptide composition that differed from the composition of strain R36A (see the HPLC chromatograms of Figs. 2 and 3; see also Table III). Strain DE1 had a high percentage of branched peptides with alanine as the first residue of the cross-bridge (monomeric peptide I, 23.9%; dimeric peptide VI, 28.8%). The peptidoglycan of strain KY17 had an increased percentage of branched peptides with serine as the first residue of the cross-bridge (monomeric peptide 3, 29.5%; dimeric peptide 7, 21%). Introduction of the cloned murM alleles in plasmid pLS578 into strain R36A caused a significant increase in the proportion of branched peptides in the peptidoglycan of the transformants, from 41% in the recipient strain to 93 and 90% in transformants R36ApM1 and R36ApM2, respectively. Furthermore, the shifts in peptidoglycan composition observed in the transformants closely paralleled the composition of peptidoglycan in strains DE1 and KY17. In R36ApM2 carrying the murM allele from DE1, the amount of peptides with alanyl-alanine branches increased from 1.7 to 24.7% (peptide I) and from 4.0 to 40.8% (peptide VI). In the peptidoglycan of R36ApM3 carrying the murM allele from strain KY17, the amount of peptides with seryl-alanine branches increased from 2.7 to 19.9% (peptide III) and from 6.5 to 23.3% (peptide 7).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   Analysis of cell wall stem peptides by RP-HPLC of several strains. Cell walls were prepared from strains R36A and DE1 and R36A transformant with the murM from DE1 (R36ApM2); strain KY17 and the R36A transformant with the KY17 murM allele (R36ApM3). Peptidoglycan compositions were analyzed by RP-HPLC.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Structural assignments for the pneumococcal stem peptides. The structures of the stem peptides found in the peptidoglycan of S. pneumoniae have been described previously (2, 24).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Cell wall stem peptide composition of various strains of S. pneumoniae

Although the peptidoglycan composition of the R36A transformants and the respective clinical isolates from which the two murM alleles were amplified was very similar, there were also several differences. For instance, strain DE1 had a higher percentage of linear monomeric peptide 1 and 6 than the R36ApM2 (Table III). Such variation may be the result of a higher expression of the cloned murM alleles, which are under the control of the strong and conserved promoter of pLS578 in the transformant (10). This is also suggested by the fact that, when the murM allele from R36A was introduced through R36ApM1, the peptidoglycan of the transformant showed a major increase in the percentage of branched peptides from 41 to 93% whereas the proportion of the branched peptide, containing serine and alanine or only alanine in the cross-bridge composition, remained unaltered (Table III and Fig. 4). In the peptidoglycan of R36ApM1 carrying the murM allele from strain R36A in the plasmid (in addition to the chromosomal encoded), the amount of peptides with seryl-alanine branches increased from 2.7 to 20.2% (peptide III) and from 6.5 to 24.5% (peptide 7).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   Role of MurM alleles in defining the chemical composition of branched cell wall stem peptides. A, peptidoglycan composition of strains carrying different murM alleles. B, schematic representation of the mosaic regions in the murM alleles. The black region indicates more than 10% divergence relatively to the MurM from the penicillin-susceptible reference strain R36A. C, distribution of polymorphic sites among the different MurM proteins. The murM alleles were sequenced from the penicillin-susceptible laboratory strain R36A and from the penicillin-resistant strains listed (5). Numbers above the sequences (beginning at the first residue of MurM: residue 10) identify positions at which an amino acid alteration was detected in one of the MurM proteins. Only positions with altered residues are shown; residues identical to those in strain R36A are indicated by dots.

These results show that, although there are two copies of murM (one in the chromosome and one in the pLS578 plasmid) in the R36A transformants, the composition of the peptidoglycan of these strains is determined by the plasmid-encoded murM, present in a much higher copy number or under the control of a stronger promoter. Additionally, the overexpression of the murM protein did not alter the specificity of the reaction. The strain R36A, with only a copy of the murM in the chromosome, had a small percentage of branched peptides that were identical to the transformant overexpressing the same protein in the pLS578 plasmid.

Besides the changed peptidoglycan composition no major changes were apparent in other properties of strain R36A transformed with the various murM alleles: The growth rate (mass doubling time) of strain R36A carrying pLS578 without insert was 28 min and with insert (e.g. R36ApM2) was 31 min. In none of the transformants carrying murM alleles from resistant strains was there any observable increase in the penicillin MIC value of strain R36A (MIC = 0.032 µg/ml as determined by E test).

Determination of the Amino Acid Sequence That Controls the Specificity of the MurM-catalyzed Branching Reaction-- Strain DE1 and the plasmid transformant R36ApM2 carrying the murM allele of DE1 produced peptidoglycan that was enriched for alanyl-alanine-containing branched peptides. In strain KY17 and its corresponding plasmid transformant R36ApM3, the peptidoglycan was enriched for seryl-alanine-containing branches. Comparison of the different mosaic murM sequences of these strains and the peptidoglycan composition suggested that the sequence that defines specificity of the branching reaction resides in the polymorphic regions of murM, specifically within the amino acid residues 229-300 (see Fig. 4C). To more precisely locate this region, chimeric mutants of murM were constructed from segments of the murM gene from strains DE1, KY17, and R36A (Fig. 3).

The mutant alleles that resulted from permuting different regions of the MurM protein from strains R36A, KY17, and DE1 were cloned into plasmid pLS578, which was then introduced into strain R36A by genetic transformation, and the peptidoglycan composition of the transformants was analyzed.

Plasmid pM9 was constructed to carry a murM allele that encoded a protein with residues 1 through 240 from the R36A MurM, and residues 241 through 406 were from strain DE1. The peptidoglycan of transformant R36ApM9 was enriched for branched peptides with alanine as the first residue of the cross-bridge (81% of all branched peptides), and this was similar to the composition of peptidoglycan in strain DE1 and in R36ApM2. Virtually identical results were obtained with construct pM10 in which the cloned MurM had residues 1 through 240 that were derived from strain KY17 and residues 241 through 406 came from DE1. In transformant R36ApM10, the percentage of branched peptides with alanine as the first residue of the cross-bridge was 80%. These results suggested that the control of specificity of the MurM-catalyzed reaction was within the 241-406 sequence of the protein.

To further define this region two additional fusion mutants were constructed. Plasmid pM11 had a cloned MurM with the entire amino acid sequence derived from the MurM of strain KY17 except for the sequence between residues 244 and 298, which was identical to that of the MurM from strain DE1. The peptidoglycan of transformant R36ApM11 was enriched for branched peptides with only alanine residues in the cross-bridge (82%). These results narrowed down the region responsible for the reaction specificity to the sequence between residues 244 and 298. In the second fusion mutant pM12, the entire cloned MurM was from strain KY17 except for the sequence between residues 244 and 274, which came from strain DE1. The peptidoglycan composition of transformant R36ApM12 was again very similar to that of strain DE1 or transformants R36ApM11 and R36ApM2: 81% of the branched peptides of this transformant were composed of alanyl-alanine.

Attempts to pinpoint individual amino acid residues within the 30-amino acid sequence between residues 244 and 274 were only partially successful. In the MurM from strain KY17 (which incorporates mainly serine) the amino acid residue at position 260 is threonine, whereas in the MurM from strain DE1 (which incorporates mainly alanine) position 260 is a lysine. In plasmid pM17, carrying an intact murM allele from strain KY17, the codon encoding the threonine at position 260 was mutated by site-directed mutagenesis to one that encoded lysine. In the corresponding transformant R36ApM17, the proportion of branched peptides increased from 41 to 92% indicating that the mutant protein was highly active. The increased amount of branched peptides is very similar to the value of 93% in the R36ApM1 transformant. However, the percentage of the branched peptides that had alanine as the first residue of the cross-bridge was only increased from 27% (in strain R36ApM3) to 46% in R36ApM17. In transformants carrying the entire 30-amino acid sequence between residues 244 and 274 from strain DE1, the corresponding increase in alanine containing cross-bridges was much larger: from 27 to 81% (see Fig. 5). These results indicate that residues other than lysine in position 260 are also involved with defining the specificity of MurM.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   Regions in the MurM proteins that define the chemical composition of branched stem peptides. The sequence of murM alleles characteristic of strains R36A (cross-hatched), DE1 (black), and KY17 (white), and the murM chimera mutants and murM deletions, are indicated by the drawings. The percentages of branched peptides that have serine or alanine in the first position of the cross-bridge are also tabulated for the various strains and murM constructs.

In two other MurM mutants cloned into pLS578, the glutamine residue in position 27 of the MurM of strain KY17 was mutated to glutamate (in pM18) or to threonine (in pM19). This amino acid has been suggested as being involved in the catalytic site of a homologous protein in Lactobacillus viridescens (21). The proportion of branched peptides was found to be normally increased in transformants carrying these mutant forms of the KY17 murM allele, but there was no change in the chemical composition of the branches.

Analysis of MurM Deletion Mutants-- Several deletion mutants were constructed from the murM allele of strain KY17, and the deleted murMs cloned into pLS578 were introduced into strain R36A by genetic transformation. No activity could be detected by plasmids carrying murM genes from which 50 amino acid residues were removed at the C terminus (pM13), the N terminus (pM14), or 10 amino acids removed at the C terminus (pM15) or in plasmids in which the sequence of MurM between residues 240 and 274 were deleted. The peptidoglycan of such transformants showed no increase in the percentage of branched structured stem peptides (see Fig. 5).

Construction of a Pen6 murM Null Mutant and Complementation with murM Encoded in a Plasmid-- To rule out the possibility that the R36A chromosome encoded MurM may have a significant contribution in the alteration in the cell wall composition, we constructed a mutant in which the murM gene was replaced by the erm marker from the pJDC9 plasmid (22). Confirmation of the erythromycin-resistant Pen6 murM null mutant was obtained by sequencing the PCR fragment amplified with primers ZOO30 and ZOO45EC (including the murMN region). Cell wall analysis showed no branched structured stem peptides in the Pen6Delta murM mutant. The composition of the peptidoglycan was identical to that of Pen6murMN, a mutant obtained by insertion of a suicide plasmid in the murM gene (4). We cloned two different MurM constructs with different specificities for alanine and serine in the murM null mutant. One of these constructs was the MurM from the penicillin-resistant strain KY17, which has serine-rich branched peptides. Analysis of the cell wall composition showed an accumulation of a peptide with retention time similar to that of the semi-branched peptide 3a (data not shown), carrying only a single serine residue in the cross-bridge (6). This result suggests that the expression of murN gene in the chromosome with the erm promoter was not sufficient to fully recover the cell wall composition. To compensate for this, both genes (the murM allele from KY17 and the murN gene from R36A strain) were cloned in pLS578 under the control of the conserved plasmid promoter and were transformed into Pen6Delta murM. The composition of the peptidoglycan of this transformant (Pen6Delta murMpM3N) was rich in serine-containing branched peptides, similar to the composition found in the KY17 strain (Table II). There was a decrease in the percentage of linear stem peptide 1 from 41.4% in Pen6Delta murM to 1% in the transformant. This value was similar to the 3.2% found in R36ApM3. There was also a decrease in the linear dimeric peptide 4 from 45.4% in Pen6Delta murM to 3.5% in the transformant. This value was similar to the 0.6% found in R36ApM3. The proportion of branched peptide 3 increased from 0.1 to 19.3% and so did the corresponding dimeric peptide 7, from 0.4 to 25% (Table III). The corresponding values for peptides 3 and 7 in the R36ApM3 transformants were 19.9 and 23.3%, respectively. The percentage of all branched peptides changed from 6% in the Pen6Delta murM mutant to 86% in the transformant carrying the pM3N plasmid. Of these branched peptides, 75% had serine as the first residue of the cross-bridge whereas in the remaining 25% the first residue was alanine. This proportion is very similar to that found in R36ApM3 (73 and 27%, respectively).

Additionally, we cloned a derivative from the DE1 murM allele, a chimeric murM mutant in which residues 1-240 came from the MurM of R36A, and residues 241-406 from the MurM of strain DE1. This construct specifically incorporated alanine when cloned into strain R36A (R36ApM9) (Fig. 5). This murM allele was cloned together with the murN gene in pLS578 (pM9N) and transformed into the Pen6 murM null mutant. The peptidoglycan of this construct was enriched in branched peptides with alanine as the first residue of the cross-bridge, as expected from the cell wall composition of DE1 strain. The percentage of linear peptides 1 and 4 was reduced to 1.0 and 0.8%, respectively. Similar values, 0.9 and 0.8, were found in R36ApM9. Concomitantly, there was accumulation of branched stem peptides with only alanine in the cross-bridge. The proportion of peptide I increased from 0.1 to 24.3% and peptide VI from 0.6 to 33.2%. The corresponding values in R36ApM9 were 26 and 45.8%, respectively. The total amount of branched peptides increased from 6% in the Pen6Delta murM mutant to 96% in the transformant with plasmid pM9N.

These results make it unlikely that the chromosomally encoded MurM from R36A has made a significant contribution to the cell wall structure in R36A transformants carrying the plasmid encoded MurM.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A unique feature of the peptidoglycan of S. pneumoniae is that it contains both linear as well as branched stem peptide residues, and dimeric and higher oligomeric components are cross-linked both directly as well as indirectly through short cross-bridges composed of dipeptides of either alanyl-alanine or seryl-alanine residues. This feature of the pneumococcal cell wall positions it as a mixed A3 alpha and A1 alpha type in the taxonomic scheme proposed by Schleifer and Kandler (23). The introduction of the RP-HPLC method for the analysis of pneumococcal cell walls (2, 24, 25) has resolved the pneumococcal peptidoglycan to a large number (over 25) of muropeptide components allowing the identification of the chemical structures of these linear and branched cell wall components. Examination of a large number of S. pneumoniae clinical isolates recovered from different isolation and geographic sites, at different time periods and expressing a variety of different capsular serotypes, showed that the muropeptide composition of the cell walls was preserved with remarkable accuracy from strain to strain, suggesting the existence of a cell wall composition that is specific for the species of S. pneumoniae (1-3). The notion of precise genetic control over cell wall composition has received new support through the examination of cell wall composition in penicillin-resistant S. pneumoniae clinical isolates. Several genetic lineages of these resistant bacteria showed an unusually large proportion of branched structured muropeptides in their cell walls, and the cell wall composition also appeared to be specific for the particular clone in terms of the chemical nature of the branched peptides: In some of the clones the amino acid serine predominated as the first amino acid of the dipeptide branch, whereas in other clones the first amino acid was alanine.

What made this structure variation particularly interesting was the observation made in 1990 that the abnormal, highly branched, cell wall composition of a penicillin-resistant South African isolate of S. pneumoniae was co-transferred along with the penicillin resistance trait during genetic transformation in which resistance to penicillin was selected for (8, 15). This finding suggested some functional connection between the abundance of branched stem peptides in the cell wall and resistance to penicillin.

The recent identification of the murMN operon in S. pneumoniae has opened up this area for new exploration. Inactivation of the murMN operon was reported to cause a disappearance of branched stem peptides from the cell wall and also a complete suppression of the penicillin-resistant phenotype. This indicated to us that further exploration of the mode of action and regulation of this operon would yield valuable new insights both into the mechanism of control of cell wall structure and also into the mechanism of expression of penicillin resistance (4).

Comparison of the DNA sequences of murM and murN genes was determined in a large number of penicillin-susceptible and penicillin-resistant clinical isolates of S. pneumoniae. Although the structure of murN genes appeared to be highly conserved showing little sequence variation, a considerable amount of polymorphism was noted in murM genes identified in several penicillin-resistant S. pneumoniae isolates (5). The site of involvement of these two genes in the production of the dipeptide branches was clarified (6). Selective inactivation of murN produced a unique type of peptidoglycan not seen among clinical isolates: Such bacteria contained branched stem peptides made up of only a single amino acid residue, the chemical nature of which remained the same as in the parental strain. Besides reduction of the dipeptide branches to a single amino acid, there was no other change in the nature and/or proportion of various structurally distinct muropeptides or in the degree of peptidoglycan cross-linking in these murN mutants. These observations identified the role of murN as the determinant involved with the addition of the second amino acid residue to the dipeptide branches. In concordance with the highly conserved sequence of murN, the nature of the second amino acid residue in the branched peptides was invariably alanine in all the large number of S. pneumoniae isolates examined.

The results of these studies suggested that the primary determinant responsible for the clone-specific variation in the structure of the pneumococcal cell walls was the murM gene, and the results of experiments described in this communication provide unequivocal evidence for this proposition.

The evidence identifying murM as the gene primarily responsible for the clone-specific variation in the pneumococcal cell wall was based on an experimental system in which the various murM alleles identified in S. pneumoniae isolates were cloned in the pneumococcal plasmid pLS578, which is capable of independent replication in pneumococci (10). These recombinant plasmids were then introduced into the isogenic background of the penicillin-susceptible S. pneumoniae strain R36A, and the activity and specificity of the particular murM allele were assessed by determining the impact of the plasmid-borne murM genes on the composition of the peptidoglycan of such transformants. The particular murM alleles used in most of these genetic crosses were murMA, carried by penicillin-susceptible strains of S. pneumoniae, murMB3 carried by the penicillin-resistant strain DE1, and murMB5 carried by the penicillin-resistant strain KY17 (5). Strains carrying murMA produce branched peptides the majority of which (71%) have serine as the first amino acid residue. Strains carrying the murMB3 allele have branched peptides in which most of the amino acid residues (82%) in the first position of the branches is alanine. In strains that carry the murMB5 allele, the first amino acid residue in the branches (78%) is serine. Analysis of these genetic crosses demonstrated the importance of the particular murM allele both for the percentage representation of branched peptides in the cell wall and also for their chemical nature. The experiments documented in Fig. 5 indicate that the abundance of branched muropeptides in the cell wall depends on the rate of transcription and/or copy number of murM. Introduction of each one of the murM alleles on plasmid pLS578, even the allele murMA identical to the one resident on the chromosome of the recipient cell R36A, caused a massive increase in the percentage of branched peptides in the cell wall. The most likely interpretation of this finding is that the well documented activity of the powerful promoter present on plasmid pLS578 (10) causes extensive transcription of murM in the transformants.

The experiments with the genetic crosses also provide clear documentation that the chemical nature of the branched peptides, i.e. whether the first amino acid residue is serine or alanine, is primarily determined by the structure of the MurM protein. The composition of the peptidoglycan of strain R36A that was the common recipient in all the genetic crosses has undergone extensive changes from serine-rich to alanine-rich branched peptides and also in the percentage of total branched peptides by the introduction of the appropriate murM alleles.

Experiments with the murM deletion mutants showed that these activities of the MurM protein depended on intact C and N termini of the protein. Deletion of 10 or 50 amino acid residues from the C terminus or removal of 50 amino acids from the N terminus caused inactivation of the MurM protein.

The chemical specificity of murM, i.e. whether the protein catalyzed the introduction of serine or alanine as the first residue of the branched peptides, was localized to a 30-amino acid sequence between residues 244 and 274 of the protein.

Biochemical analysis of the cell wall precursor pools has identified the lipid II as the substrate of the MurM protein. This is in contrast to the recently described case for Lactobacillus viridescens in which cell wall branched peptides were shown to be attached to the disaccharide pentapeptide precursor in the cytoplasmic stage of cell wall biosynthesis (21, 26). Our data show that in S. pneumoniae this reaction takes place in the plasma membrane.

The large variation in peptidoglycan composition identified in the plasmid transformants did not seem to cause any perceptible growth defect in the transformants nor in the morphology of the bacteria. Despite the radical changes in the proportion of branched peptides and also in the chemical nature of the branches, other aspects of the structure of peptidoglycan such as the proportion of monomeric and oligomeric muropeptides or the degree of cross-linking remained unchanged in the genetic transformants. In the plasmid transformants R36ApM2 and R36ApM3, the total number of branched muropeptides increased from 41% in strain R36A to 90 and 89%, respectively, in the transformants. Despite this radical change in wall composition, bacterial growth was not perceptively affected indicating that the penicillin binding proteins of the penicillin-susceptible strain R36A were able to utilize either linear or branched peptides with equal facility for cell wall biosynthesis.

It is also clear from the results that the introduction of murM alleles from penicillin-resistant bacteria to the penicillin-susceptible recipient R36A did not cause any increase in penicillin resistance. It seems that the presence of low affinity penicillin binding proteins remains an indispensable prerequisite for the resistant phenotype. The mechanism responsible for the dramatic loss of penicillin resistance in S. pneumoniae with inactivated murMN is the subject of a forthcoming communication.2

    ACKNOWLEDGEMENT

We are grateful to Dr. Sandford Lacks for plasmid pLS578.

    FOOTNOTES

* This work was supported in part by a grant from the National Institutes of Health RO1-AI37275 and by the Irene Diamond Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by grant BD/9071/96 from PRAXIS XXI from Fundação para a Ciência e Tecnologia.

|| Permanent address: Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Moscow Region 142292, Russia.

** To whom correspondence should be addressed: Laboratory of Microbiology, The Rockefeller University, 1230 York Ave., New York, NY 10021. Tel.: 212-327-8278; Fax: 212-327-8688; E-mail: tomasz@mail.rockefeller.edu.

Published, JBC Papers in Press, August 24, 2001, DOI 10.1074/jbc.M106425200

2 S. R. Filipe, E. Severina, and A. Tomasz, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: MIC, minimal inhibitory concentration; PCR, polymerase chain reaction; kb, kilobase(s); RP-HPLC, reversed-phase high pressure liquid chromatography; aa, amino acid(s).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Garcia-Bustos, J., and Tomasz, A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5415-5419[Abstract/Free Full Text]
2. Severin, A., and Tomasz, A. (1996) J. Bacteriol. 178, 168-174[Abstract/Free Full Text]
3. Severin, A., Figueiredo, A. M., and Tomasz, A. (1996) J. Bacteriol. 178, 1788-1792[Abstract/Free Full Text]
4. Filipe, S. R., and Tomasz, A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4891-4896[Abstract/Free Full Text]
5. Filipe, S. R., Severina, E., and Tomasz, A. (2000) J. Bacteriol. 182, 6798-6805[Abstract/Free Full Text]
6. Filipe, S. R., Pinho, M. G., and Tomasz, A. (2000) J. Biol. Chem. 275, 27768-27774[Abstract/Free Full Text]
7. Avery, O. T., Macleod, C. M., and McCarty, M. (1944) J. Exp. Med. 79, 137-157[Abstract]
8. Zighelboim, S., and Tomasz, A. (1980) Antimicrob. Agents Chemother. 17, 434-442[Abstract/Free Full Text]
9. Corso, A., Severina, E. P., Petruk, V. F., Mauriz, Y. R., and Tomasz, A. (1998) Microb. Drug Resist. 4, 325-337[Medline] [Order article via Infotrieve]
10. Lacks, S. A., Ayalew, S., de la Campa, A. G., and Greenberg, B. (2000) Mol. Microbiol. 35, 1089-1098[CrossRef][Medline] [Order article via Infotrieve]
11. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1996) Current Protocols in Molecular Biology , John Wiley & Sons, New York
12. Sambrook, J., Fritsch, I., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
13. Marmur, J. (1961) J. Mol. Biol. 3, 208-218
14. Pozzi, G., Masala, L., Iannelli, F., Manganelli, R., Havarstein, L. S., Piccoli, L., Simon, D., and Morrison, D. A. (1996) J. Bacteriol. 178, 6087-6090[Abstract/Free Full Text]
15. Garcia-Bustos, J. F., Chait, B. T., and Tomasz, A. (1988) J. Bacteriol. 170, 2143-2147[Abstract/Free Full Text]
16. Garcia-Bustos, J. F., and Tomasz, A. (1987) J. Bacteriol. 169, 447-453[Abstract/Free Full Text]
17. Ornelas-Soares, A., de Lencastre, H., de Jonge, B. L., and Tomasz, A. (1994) J. Biol. Chem. 269, 27246-27250[Abstract/Free Full Text]
18. Kohlrausch, U., and Holtje, J. V. (1991) J. Bacteriol. 173, 3425-3431[Abstract/Free Full Text]
19. de Jonge, B. L., Chang, Y. S., Gage, D., and Tomasz, A. (1992) J. Biol. Chem. 267, 11248-11254[Abstract/Free Full Text]
20. Atherton, D. (1989) in Techniques in Protein Chemistry (Hugli, T. E., ed) , pp. 273-283, Academic Press, New York
21. Hedge, S. S., and Shrader, T. E. (2001) J. Biol. Chem. 276, 6998-7003[Abstract/Free Full Text]
22. Chen, J. D., and Morrison, D. A. (1988) Gene 64, 155-164[CrossRef][Medline] [Order article via Infotrieve]
23. Schleifer, K. H., and Kandler, O. (1972) Bacteriol. Rev. 36, 407-477[Free Full Text]
24. Garcia-Bustos, J. F., Chait, B. T., and Tomasz, A. (1987) J. Biol. Chem. 262, 15400-15405[Abstract/Free Full Text]
25. Severin, A., Schuster, C., Hakenbeck, R., and Tomasz, A. (1992) J. Bacteriol. 174, 5152-5155[Abstract/Free Full Text]
26. Plapp, R., and Strominger, J. L. (1970) J. Biol. Chem. 245, 3675-3682[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
A. J. Lloyd, A. M. Gilbey, A. M. Blewett, G. De Pascale, A. El Zoeiby, R. C. Levesque, A. C. Catherwood, A. Tomasz, T. D. H. Bugg, D. I. Roper, et al.
Characterization of tRNA-dependent Peptide Bond Formation by MurM in the Synthesis of Streptococcus pneumoniae Peptidoglycan
J. Biol. Chem., March 7, 2008; 283(10): 6402 - 6417.
[Abstract] [Full Text] [PDF]


Home page
Microbiol. Mol. Biol. Rev.Home page
J. van Heijenoort
Lipid Intermediates in the Biosynthesis of Bacterial Peptidoglycan
Microbiol. Mol. Biol. Rev., December 1, 2007; 71(4): 620 - 635.
[Abstract] [Full Text] [PDF]


Home page